Cargando…

Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)

BACKGROUND: The CLARINET-MS study assessed the long-term effectiveness of cladribine tablets by following patients with multiple sclerosis (MS) in Italy, using data from the Italian MS Registry. METHODS: Real-world data (RWD) from Italian MS patients who participated in cladribine tablets randomised...

Descripción completa

Detalles Bibliográficos
Autores principales: Patti, Francesco, Visconti, Andrea, Capacchione, Antonio, Roy, Sanjeev, Trojano, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294475/
https://www.ncbi.nlm.nih.gov/pubmed/32587633
http://dx.doi.org/10.1177/1756286420922685
_version_ 1783546494658281472
author Patti, Francesco
Visconti, Andrea
Capacchione, Antonio
Roy, Sanjeev
Trojano, Maria
author_facet Patti, Francesco
Visconti, Andrea
Capacchione, Antonio
Roy, Sanjeev
Trojano, Maria
author_sort Patti, Francesco
collection PubMed
description BACKGROUND: The CLARINET-MS study assessed the long-term effectiveness of cladribine tablets by following patients with multiple sclerosis (MS) in Italy, using data from the Italian MS Registry. METHODS: Real-world data (RWD) from Italian MS patients who participated in cladribine tablets randomised clinical trials (RCTs; CLARITY, CLARITY Extension, ONWARD or ORACLE-MS) across 17 MS centres were obtained from the Italian MS Registry. RWD were collected during a set observation period, spanning from the last dose of cladribine tablets during the RCT (defined as baseline) to the last visit date in the registry, treatment switch to other disease-modifying drugs, date of last Expanded Disability Status Scale recording or date of the last relapse (whichever occurred last). Time-to-event analysis was completed using the Kaplan–Meier (KM) method. Median duration and associated 95% confidence intervals (CI) were estimated from the model. RESULTS: Time span under observation in the Italian MS Registry was 1–137 (median 80.3) months. In the total Italian patient population (n = 80), the KM estimates for the probability of being relapse-free at 12, 36 and 60 months after the last dose of cladribine tablets were 84.8%, 66.2% and 57.2%, respectively. The corresponding probability of being progression-free at 60 months after the last dose was 63.7%. The KM estimate for the probability of not initiating another disease-modifying treatment at 60 months after the last dose of cladribine tablets was 28.1%, and the median time-to-treatment change was 32.1 (95% CI 15.5–39.5) months. CONCLUSION: CLARINET-MS provides an indirect measure of the long-term effectiveness of cladribine tablets. Over half of MS patients analysed did not relapse or experience disability progression during 60 months of follow-up from the last dose, suggesting that cladribine tablets remain effective in years 3 and 4 after short courses at the beginning of years 1 and 2.
format Online
Article
Text
id pubmed-7294475
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-72944752020-06-24 Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS) Patti, Francesco Visconti, Andrea Capacchione, Antonio Roy, Sanjeev Trojano, Maria Ther Adv Neurol Disord Original Research BACKGROUND: The CLARINET-MS study assessed the long-term effectiveness of cladribine tablets by following patients with multiple sclerosis (MS) in Italy, using data from the Italian MS Registry. METHODS: Real-world data (RWD) from Italian MS patients who participated in cladribine tablets randomised clinical trials (RCTs; CLARITY, CLARITY Extension, ONWARD or ORACLE-MS) across 17 MS centres were obtained from the Italian MS Registry. RWD were collected during a set observation period, spanning from the last dose of cladribine tablets during the RCT (defined as baseline) to the last visit date in the registry, treatment switch to other disease-modifying drugs, date of last Expanded Disability Status Scale recording or date of the last relapse (whichever occurred last). Time-to-event analysis was completed using the Kaplan–Meier (KM) method. Median duration and associated 95% confidence intervals (CI) were estimated from the model. RESULTS: Time span under observation in the Italian MS Registry was 1–137 (median 80.3) months. In the total Italian patient population (n = 80), the KM estimates for the probability of being relapse-free at 12, 36 and 60 months after the last dose of cladribine tablets were 84.8%, 66.2% and 57.2%, respectively. The corresponding probability of being progression-free at 60 months after the last dose was 63.7%. The KM estimate for the probability of not initiating another disease-modifying treatment at 60 months after the last dose of cladribine tablets was 28.1%, and the median time-to-treatment change was 32.1 (95% CI 15.5–39.5) months. CONCLUSION: CLARINET-MS provides an indirect measure of the long-term effectiveness of cladribine tablets. Over half of MS patients analysed did not relapse or experience disability progression during 60 months of follow-up from the last dose, suggesting that cladribine tablets remain effective in years 3 and 4 after short courses at the beginning of years 1 and 2. SAGE Publications 2020-06-10 /pmc/articles/PMC7294475/ /pubmed/32587633 http://dx.doi.org/10.1177/1756286420922685 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Patti, Francesco
Visconti, Andrea
Capacchione, Antonio
Roy, Sanjeev
Trojano, Maria
Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)
title Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)
title_full Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)
title_fullStr Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)
title_full_unstemmed Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)
title_short Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)
title_sort long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the italian multiple sclerosis registry (clarinet-ms)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294475/
https://www.ncbi.nlm.nih.gov/pubmed/32587633
http://dx.doi.org/10.1177/1756286420922685
work_keys_str_mv AT pattifrancesco longtermeffectivenessinpatientspreviouslytreatedwithcladribinetabletsarealworldanalysisoftheitalianmultiplesclerosisregistryclarinetms
AT viscontiandrea longtermeffectivenessinpatientspreviouslytreatedwithcladribinetabletsarealworldanalysisoftheitalianmultiplesclerosisregistryclarinetms
AT capacchioneantonio longtermeffectivenessinpatientspreviouslytreatedwithcladribinetabletsarealworldanalysisoftheitalianmultiplesclerosisregistryclarinetms
AT roysanjeev longtermeffectivenessinpatientspreviouslytreatedwithcladribinetabletsarealworldanalysisoftheitalianmultiplesclerosisregistryclarinetms
AT trojanomaria longtermeffectivenessinpatientspreviouslytreatedwithcladribinetabletsarealworldanalysisoftheitalianmultiplesclerosisregistryclarinetms
AT longtermeffectivenessinpatientspreviouslytreatedwithcladribinetabletsarealworldanalysisoftheitalianmultiplesclerosisregistryclarinetms